ÂÜÀòÂÒÂ×

Kevin Knockenhauer has over 10 years of work experience. Kevin started as an Undergraduate Research Assistant at Stony Brook University in 2007, working on a project to characterize proteins encapsulated within solid-state nanofibers. Kevin then moved to Massachusetts Institute of Technology in 2011, where they worked as a Postdoctoral Associate and Graduate Student, researching the Y subcomplex of the nuclear pore, the BBSome from the primary cilium, and CDPK1 from the parasite Toxoplasma gondii. In 2016, they joined Novartis Institutes for BioMedical Research (NIBR) as a Postdoctoral Scholar. In 2017, they joined Bioverativ, a Sanofi company, as a Scientist I. In 2018, they moved to Sanofi as a Scientist I and Scientist II, working in the Rare Blood Disorders Therapeutic Area. In 2020, they joined Civetta Therapeutics as a Senior Scientist, and in 2021 they moved to Accent Therapeutics, Inc. as an Associate Director and Principal Scientist.

Kevin Knockenhauer obtained a Bachelor of Science (B.S.) in Biochemistry from Stony Brook University between 2006 and 2010. Kevin then went on to pursue a Doctor of Philosophy (Ph.D.) in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology, which they completed in 2015.